Revenue
2022
2023
2024
2025
Invivyd, Inc. (IVVD)
Price$0.8260Cached quote
Net income
2021
2021
2021
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2021
2021
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 · Dec 31 | 2021 · Sep 30 | 2021 · Jun 30 | 2021 · Mar 31 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | $0 | — | — | — | — |
| Research & development | $38.3M | $137.3M | $158.7M | $179.2M | $182.9M | — | — | — |
| Operating expenses | $109.0M | $202.3M | $212.8M | $248.0M | $226.9M | — | — | — |
| Operating income | −$55.6M | −$176.9M | −$212.8M | −$248.0M | −$226.9M | — | — | — |
| Operating margin | −103.99% | −696.80% | — | — | — | — | — | — |
| EBITDA | −$53.5M | −$173.8M | −$212.3M | −$248.0M | −$226.9M | — | — | — |
| EBITDA margin | −100.05% | −684.54% | — | — | — | — | — | — |
| Net income | −$52.5M | −$169.9M | −$198.6M | −$241.3M | −$226.8M | −$143.7M | −$83.4M | −$38.7M |
| Net profit margin | −98.25% | −669.42% | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.30 | -$1.43 | -$1.81 | -$2.23 | -$5.32 | — | — | — |
| Diluted EPSper diluted share | -$0.30 | -$1.43 | -$1.81 | -$2.23 | -$5.32 | — | — | — |
Owners
Reported shareholders
11.59%of listed shares
Jupiter Topco LLC34.17M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Jupiter Topco LLC | 11.59%34.17M shares |
BVF INC/IL | 9.56%28.17M shares |
MAVERICK CAPITAL LTD | 6.44%18.97M shares |
PERCEPTIVE ADVISORS LLC | 6.27%18.49M shares |
BlackRock, Inc. | 5.47%16.13M shares |
Royan Ajay | ≈3.81%11.24M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.56%10.5M shares |
M28 Capital Management LP | 3.14%9.25M shares |
Saturn V Capital Management LP | 2.85%8.39M shares |
Soleus Capital Management, L.P. | 2.62%7.71M shares |
Point72 Asset Management, L.P. | 2.56%7.54M shares |
MCGUIRE TERRANCE | ≈2.31%6.8M shares |
MORGAN STANLEY | 1.94%5.73M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.84%5.42M shares |
Siren, L.L.C. | 1.70%5M shares |
Driehaus Capital Management LLC | 1.63%4.81M shares |
ADAR1 Capital Management, LLC | 1.29%3.81M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.24%3.66M shares |
CITADEL ADVISORS LLC | 1.21%3.58M shares |
STATE STREET CORP | 1.17%3.46M shares |
Percentages use 294.76M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2026Form 4 · 10b5-1 | Allen Robert D. IIIChief Scientific Officer | SellCommon Stock | 19.4K | $1.58 | $30.6K | 114.5K |
| Feb 18, 2026Form 4 · 10b5-1 | Green JulieChief Human Resources Officer | SellCommon Stock | 21.0K | $1.58 | $33.1K | 107.7K |
| Feb 18, 2026Form 4 · 10b5-1 | Duke William E.Chief Financial Officer | SellCommon Stock | 21.0K | $1.58 | $33.1K | 107.7K |
| Feb 18, 2026Form 4 · 10b5-1 | Lee Timothy EdwardChief Commercial Officer | SellCommon Stock | 21.0K | $1.58 | $33.1K | 117.7K |
| Feb 18, 2026Form 4 · 10b5-1 | Andersen JillChief Legal Officer, Secretary | SellCommon Stock | 34.9K | $1.58 | $55.2K | 181.7K |
Community posts
Invivyd reports favorable Phase 3 tolerability results and outlines filing plans
Invivyd ($IVVD) said its investigational antibody VYD2311 met the primary and key secondary safety endpoints in LIBERTY, a randomized study involving 210 healthy adults aged 18–49. Within six days, 56.5% of antibody recipients reported an a ...
